TY - JOUR
KW - Neglected tropical diseases (NTDs)
KW - Visceral Leishmaniasis
KW - Amphoterecin B
KW - Kala-Azar
KW - Miltefosine
KW - Paromomycin
KW - chemotherapeutics
KW - Treatment
AU - Sundar S
AU - Singh A
AB - <p>Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options. Long duration of treatment and drug toxicity further limit the target of achieving VL elimination. Chemotherapy remains the treatment of choice. Single dose of liposomal amphotericin B (LAmB) and multidrug therapy (LAmB + miltefosine, LAmB + paromomycin (PM), or miltefosine + PM) are recommended treatment regimen for treatment of VL in Indian sub-continent. Combination therapy of pentavalent antimonials (Sbv) and PM in East Africa and LAmB in the Mediterranean region/South America remains the treatment of choice. Various drugs having anti-leishmania properties are in preclinical phase and need further development. An effective treatment and secondary prophylaxis of HIV-VL co-infection should be developed to decrease treatment failure and drug resistance.</p>

BT - Parasitology
C1 - <p>http://www.ncbi.nlm.nih.gov/pubmed/29215329?dopt=Abstract</p>

DO - 10.1017/S0031182017002116
J2 - Parasitology
LA - eng
N2 - <p>Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options. Long duration of treatment and drug toxicity further limit the target of achieving VL elimination. Chemotherapy remains the treatment of choice. Single dose of liposomal amphotericin B (LAmB) and multidrug therapy (LAmB + miltefosine, LAmB + paromomycin (PM), or miltefosine + PM) are recommended treatment regimen for treatment of VL in Indian sub-continent. Combination therapy of pentavalent antimonials (Sbv) and PM in East Africa and LAmB in the Mediterranean region/South America remains the treatment of choice. Various drugs having anti-leishmania properties are in preclinical phase and need further development. An effective treatment and secondary prophylaxis of HIV-VL co-infection should be developed to decrease treatment failure and drug resistance.</p>

PY - 2017
SP - 1
EP - 7
T2 - Parasitology
TI - Chemotherapeutics of visceral leishmaniasis: present and future developments.
SN - 1469-8161
ER -